Solidifying Discovery’s Position as a Chief in Lengthy Learn Sequencing and Creating Giant-Scale Lengthy Learn and Brief Learn Sequencing Providers
HUNTSVILLE, Ala., Nov. 3, 2020 /PRNewswire/ — Discovery Life Sciences™ (Discovery), a world chief in biospecimen options, genomic, cell, and immunohistochemistry (IHC) providers, declares the growth of their HudsonAlpha Discovery™ PacBio Heart of Excellence with the acquisition of further Sequel® II Methods. The brand new techniques, powered by Single Molecule, Actual-Time (SMRT®) Sequencing expertise, produce extremely correct lengthy reads, generally known as HiFi reads, and help the newest PacBio HiFi sequencing purposes.
The funding makes Discovery one of many largest industrial suppliers of lengthy learn subsequent technology sequencing providers for analysis, improvement and scientific trial purposes — with capability and confirmed expertise for large-scale initiatives together with the NIH All of Us Research Program. HudsonAlpha Discovery is Discovery Life Science’s sequencing and bioinformatics laboratory that gives a collection of long-read, short-read and strand-specific sequencing applied sciences – together with Pacific Biosciences, Illumina NovaSeq, 10x Genomic, Chromium, and Oxford Nanopore platforms, optical mapping, and variant discovery algorithms.
Lengthy-read sequencing improves de novo meeting, will increase variant detection for entire genome sequencing, comprehensively maps troublesome genomic areas, identifies transcript isoforms and elucidates complicated disease-causing components reminiscent of repeat expansions and structural variants that brief learn applied sciences miss. These benefits are driving elevated adoption of lengthy learn sequencing applied sciences, particularly within the discipline of oncology. To fulfill the rising demand with scaled, inexpensive options, Discovery now delivers expanded large-scale lengthy learn genomic sequencing providers, built-in with its complete platform that features biospecimen options, brief learn sequencing, nucleic acid isolation, IHC and movement cytometry providers.
“HudsonAlpha Discovery is uniquely positioned to help the rising want for large-scale lengthy learn sequencing in most cancers, drug, and diagnostic analysis and improvement,” stated Dr. Shawn Levy, PhD, Chief Scientific Officer Discovery Life Sciences. “Our experience is centered on high-throughput sequencing, workflow optimization, and creating cutting-edge analytical pipelines in help of worldwide, large-scale scientific trial packages.”
“PacBio is happy to help HudsonAlpha Discovery, a number one sequencing service supplier, in increasing their HiFi sequencing capability to fulfill the rising demand for long-read sequencing initiatives,” stated Chris Siepert, VP Gross sales and Help for the Americas and Europe at PacBio. “We’re wanting ahead to additional increasing our collaboration with Discovery to help a full suite of HiFi sequencing purposes and genetic evaluation strategies to assist advance analysis regarding the analysis and therapy of illness, together with most cancers.”
About Discovery Life Sciences
Discovery Life Sciences is the worldwide market chief in biospecimen evaluation, procurement, distribution, and scientific providers for the pharmaceutical, biotechnology, and diagnostics industries. HudsonAlpha Discovery is Discovery’s globally acknowledged sequencing and bioinformatics division that leverages essentially the most present genomic analysis applied sciences to comprehensively help discovery, translational, and scientific analysis. Pushed by science, the Discovery staff engages with clients in an revolutionary, consultative strategy to overcoming obstacles and reaching a sooner finish consequence. We’re Science at your Service™! For extra data, go to dls.com.
SOURCE Discovery Life Sciences